Popular on s4story
- Beyond Wealth and Recognition: Caribbean Author Lyndon Alexander Hall Redefines Success - 232
- Sycamore Dove Releases "Loving Every Moment" - 184
- Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs - 116
- North Carolina Author Carrie Sybert Celebrates Three Published Books - 111
- When Family Fails, Who Shows Up? Sarah Spector's NEXT BEST THING Offers a Personal Answer - 106
- New Children's Picture Book "Adam's Apple" Celebrates Childhood Curiosity and the Funny Misundersta
- Author Crystal Quast featured on CBC Radio to talk about toxic influencer culture
- New Book - Future God: A Codex for Spiritual Enlightenment for Machines and Artificial Intelligence
- New Children's Picture Book "Tippy Tay" Explores the Dangers of Peer Pressure and the Importance of
- The YA Fantasy Novel of the Year.... See You in Your Sleep by R.T. Tita
Similar on s4story
- Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
- New Six-Figure Media Agreement Builds Powerful Momentum, Expanding Government Contracts, FBI Access and Growing AI Recognition: Cyabra (NAS DAQ: CYAB)
- Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
- The 4th Annual Newark Summit for Economic Development, Placemaking & Innovation Returns on December 8th
- New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
- OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
- Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs
- ZenaTech (NAS DAQ: ZENA) $1 Million in New Utility Contracts- Potential $2.5 Million Follow-On Opportunity Puts Its Drone Business in the Spotlight!
- New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
- Genuine Hospitality, LLC Selected to Operate Holiday Inn Express & Suites Jacksonville – Town Center
Nutriband Inc. (N A S D A Q: NTRB) Breaks Into Uncharted Territory: 52-Week High Eclipsed as Shares Surge 22% —AVERSA™ Puts Investors on High Alert
S For Story/10703811
$NTRB reaches a new 52-week high of $9.00 and closes at $8.99, extending a powerful September advance as the company approaches the September 30 expiration of 910,904 publicly traded warrants and continues advancing its AVERSA™ abuse-deterrent transdermal platform
ORLANDO, Fla. - s4story -- Nutriband Inc. (N A S D A Q: NTRB) delivered one of its most notable trading sessions of 2026 on September 24, breaking through its previous 52-week high and reaching $9.00 intraday before closing at $8.99, a gain of approximately 22.31% on the day. Trading volume reached roughly 382,000 shares, substantially above the approximately 130,000 shares traded on September 23. Current market data places NTRB's 52-week range at approximately $2.80–$9.00.
The move represents another dramatic step in a September rally that has brought NTRB from a $4.72 September 3 opening price to today's $8.99 close. The stock has therefore gained roughly 90% from that September 3 opening level, while the September 24 session alone added $1.64 per share.
For investors watching the company, however, the stock-price breakout is occurring at an especially interesting time.
Nutriband is simultaneously approaching a major warrant deadline, advancing intellectual-property and commercialization initiatives surrounding AVERSA™, and increasing its visibility within the Nasdaq life-sciences community.
A New 52-Week High Changes the Conversation
Today's trading session was significant not simply because NTRB rose sharply, but because the stock pushed into a new 52-week high of $9.00.
NTRB opened at $7.35, traded as low as $7.35, and then climbed to $9.00 before finishing at $8.99.
That represents a remarkable intraday move of approximately 22.4% from the opening price and puts the stock firmly into new territory for the trailing 52-week period.
The progression throughout September is also notable:
The stock's September momentum is therefore occurring against a backdrop of substantial volatility rather than a straight-line advance. That distinction is important for investors evaluating what happens next.
More on S For Story
The Warrant Clock Is Now Ticking Loudly
One of the biggest near-term developments surrounding NTRB is the company's publicly traded warrants, N A S D A Q: NTRBW.
And there has been an important update since our previous article.
On September 22, Nutriband officially confirmed that the outstanding publicly traded warrants will expire September 30, 2026 at 5:00 p.m. Eastern Time. The company specifically stated that it will not extend or reprice the warrants.
There are currently 910,904 warrants outstanding, each with a $6.43 exercise price. If every one of those warrants were exercised at $6.43, Nutriband would receive approximately $5.856 million in gross proceeds.
With NTRB closing today at $8.99, the common stock is approximately $2.56 above the $6.43 warrant exercise price.
That creates a particularly interesting situation heading into the final trading days before expiration.
Warrants that are not exercised by the deadline will expire and become void. The company has also confirmed that trading in NTRBW will cease at the close of trading on September 30.
For investors, the key numbers are now unmistakable:
910,904 — public warrants outstanding
$6.43 — exercise price
$5.856 million — potential gross proceeds if fully exercised
September 30, 2026 — expiration at 5:00 p.m. ET
AVERSA™ Remains the Bigger Story
While today's stock move is attracting attention, the fundamental development story remains Nutriband's AVERSA™ abuse-deterrent transdermal technology.
Nutriband is developing AVERSA™ Fentanyl as an abuse-deterrent fentanyl transdermal system designed to address risks associated with abuse, misuse, diversion and accidental exposure.
The company has described AVERSA™ as a platform that can be incorporated into transdermal patches containing drugs with abuse potential. Nutriband's broader AVERSA development pipeline includes additional potential applications beyond fentanyl.
Importantly, the company has also reported AVERSA-related patent protection in 46 countries, adding an extensive intellectual-property component to the potential commercial opportunity.
USPTO Development Adds Another Piece
Earlier this month, Nutriband announced that it received a USPTO Notice of Publication for commercial brand-name trademarks associated with its lead abuse-deterrent fentanyl transdermal system.
The trademarks are subject to a 30-day opposition period, after which the company could potentially proceed toward a Notice of Allowance. Nutriband has said the proposed commercial brand name and product labeling are intended for submission to the FDA and international regulatory agencies as part of its development strategy.
More on S For Story
The company has previously estimated potential peak annual U.S. sales for its abuse-deterrent fentanyl product in the range of $80 million to $200 million. That figure is a company projection, not current revenue or a guarantee of future sales.
Nasdaq Visibility Continues to Grow
Nutriband CEO Gareth Sheridan also participated in the inaugural N A S D A Q Life Sciences Advisory Board (LaB) Biotech Summit at Nasdaq MarketSite in New York on September 16.
The event brought together biotechnology executives, investors and industry participants and provided another opportunity for Nutriband management to present the company's story within the broader life-sciences investment community.
A Particularly Interesting Moment for NTRB
Today's new 52-week high arrives with several important developments converging simultaneously.
The stock has broken into new 52-week territory.
The September 30 warrant expiration is only days away.
The $6.43 warrant exercise price remains well below today's $8.99 closing price.
Up to approximately $5.856 million in gross proceeds could result if all 910,904 public warrants are exercised.
AVERSA™ continues progressing toward its potential commercialization pathway.
The company's intellectual-property and trademark position continues developing.
For prospective investors, that combination makes the next several trading sessions particularly important to watch.
Today's $9.00 52-week high and $8.99 close mark a clear technical milestone for Nutriband. At the same time, the company is approaching the end of a significant warrant window that could potentially provide additional capital while it continues developing AVERSA™.
The next chapter will ultimately depend on execution — including regulatory progress, financing, commercialization, intellectual-property development and the company's ability to advance its pipeline.
But with NTRB now trading at a new 52-week high, AVERSA™ continuing forward, and the NTRBW warrant deadline arriving September 30, Nutriband has certainly entered a period that warrants close attention as September comes to an end.
For more information on NTRB visit: https://www.nutriband.com
Nutriband, Inc.
121 South Orange Avenue
Suite 1500
Orlando, Fl 32801
Phone: 407-377-6695
Email: info@nutriband.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
The move represents another dramatic step in a September rally that has brought NTRB from a $4.72 September 3 opening price to today's $8.99 close. The stock has therefore gained roughly 90% from that September 3 opening level, while the September 24 session alone added $1.64 per share.
For investors watching the company, however, the stock-price breakout is occurring at an especially interesting time.
Nutriband is simultaneously approaching a major warrant deadline, advancing intellectual-property and commercialization initiatives surrounding AVERSA™, and increasing its visibility within the Nasdaq life-sciences community.
A New 52-Week High Changes the Conversation
Today's trading session was significant not simply because NTRB rose sharply, but because the stock pushed into a new 52-week high of $9.00.
NTRB opened at $7.35, traded as low as $7.35, and then climbed to $9.00 before finishing at $8.99.
That represents a remarkable intraday move of approximately 22.4% from the opening price and puts the stock firmly into new territory for the trailing 52-week period.
The progression throughout September is also notable:
- Sept. 3: closed at $5.63
- Sept. 11: closed at $6.96
- Sept. 17: closed at $7.65
- Sept. 18: closed at $8.13
- Sept. 23: closed at $7.35
- Sept. 24: $9.00 intraday / $8.99 close
The stock's September momentum is therefore occurring against a backdrop of substantial volatility rather than a straight-line advance. That distinction is important for investors evaluating what happens next.
More on S For Story
- Cynthia Hilston Announces the Release of It's All About Love
- The World's No.1 Superstar® Brings Christmas Back in Grand Style with Music, Cinematic Glamour, and Luxury Fashion
- New Six-Figure Media Agreement Builds Powerful Momentum, Expanding Government Contracts, FBI Access and Growing AI Recognition: Cyabra (NAS DAQ: CYAB)
- Christmas Beats Summer in Paris: Travel Photoshoots Peak on Dec. 30
- Dead Losses by John Dandola is the Fifteenth Tony Del Plato Mystery Novel
The Warrant Clock Is Now Ticking Loudly
One of the biggest near-term developments surrounding NTRB is the company's publicly traded warrants, N A S D A Q: NTRBW.
And there has been an important update since our previous article.
On September 22, Nutriband officially confirmed that the outstanding publicly traded warrants will expire September 30, 2026 at 5:00 p.m. Eastern Time. The company specifically stated that it will not extend or reprice the warrants.
There are currently 910,904 warrants outstanding, each with a $6.43 exercise price. If every one of those warrants were exercised at $6.43, Nutriband would receive approximately $5.856 million in gross proceeds.
With NTRB closing today at $8.99, the common stock is approximately $2.56 above the $6.43 warrant exercise price.
That creates a particularly interesting situation heading into the final trading days before expiration.
Warrants that are not exercised by the deadline will expire and become void. The company has also confirmed that trading in NTRBW will cease at the close of trading on September 30.
For investors, the key numbers are now unmistakable:
910,904 — public warrants outstanding
$6.43 — exercise price
$5.856 million — potential gross proceeds if fully exercised
September 30, 2026 — expiration at 5:00 p.m. ET
AVERSA™ Remains the Bigger Story
While today's stock move is attracting attention, the fundamental development story remains Nutriband's AVERSA™ abuse-deterrent transdermal technology.
Nutriband is developing AVERSA™ Fentanyl as an abuse-deterrent fentanyl transdermal system designed to address risks associated with abuse, misuse, diversion and accidental exposure.
The company has described AVERSA™ as a platform that can be incorporated into transdermal patches containing drugs with abuse potential. Nutriband's broader AVERSA development pipeline includes additional potential applications beyond fentanyl.
Importantly, the company has also reported AVERSA-related patent protection in 46 countries, adding an extensive intellectual-property component to the potential commercial opportunity.
USPTO Development Adds Another Piece
Earlier this month, Nutriband announced that it received a USPTO Notice of Publication for commercial brand-name trademarks associated with its lead abuse-deterrent fentanyl transdermal system.
The trademarks are subject to a 30-day opposition period, after which the company could potentially proceed toward a Notice of Allowance. Nutriband has said the proposed commercial brand name and product labeling are intended for submission to the FDA and international regulatory agencies as part of its development strategy.
More on S For Story
- Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
- Wordeee Announces Publication of Don Cooper's "There's Trouble In Paradise"
- Wordeee Publishes "Hold Your Seahorses" by Margie Stiles
- Canadian Author Amrinder Sahota Releases The Kindest Hunger
- Jamie Foxx's SKVLK Fest Sets the Record Straight on Stabbing Reports Following Star-Studded Celebration
The company has previously estimated potential peak annual U.S. sales for its abuse-deterrent fentanyl product in the range of $80 million to $200 million. That figure is a company projection, not current revenue or a guarantee of future sales.
Nasdaq Visibility Continues to Grow
Nutriband CEO Gareth Sheridan also participated in the inaugural N A S D A Q Life Sciences Advisory Board (LaB) Biotech Summit at Nasdaq MarketSite in New York on September 16.
The event brought together biotechnology executives, investors and industry participants and provided another opportunity for Nutriband management to present the company's story within the broader life-sciences investment community.
A Particularly Interesting Moment for NTRB
Today's new 52-week high arrives with several important developments converging simultaneously.
The stock has broken into new 52-week territory.
The September 30 warrant expiration is only days away.
The $6.43 warrant exercise price remains well below today's $8.99 closing price.
Up to approximately $5.856 million in gross proceeds could result if all 910,904 public warrants are exercised.
AVERSA™ continues progressing toward its potential commercialization pathway.
The company's intellectual-property and trademark position continues developing.
For prospective investors, that combination makes the next several trading sessions particularly important to watch.
Today's $9.00 52-week high and $8.99 close mark a clear technical milestone for Nutriband. At the same time, the company is approaching the end of a significant warrant window that could potentially provide additional capital while it continues developing AVERSA™.
The next chapter will ultimately depend on execution — including regulatory progress, financing, commercialization, intellectual-property development and the company's ability to advance its pipeline.
But with NTRB now trading at a new 52-week high, AVERSA™ continuing forward, and the NTRBW warrant deadline arriving September 30, Nutriband has certainly entered a period that warrants close attention as September comes to an end.
For more information on NTRB visit: https://www.nutriband.com
Nutriband, Inc.
121 South Orange Avenue
Suite 1500
Orlando, Fl 32801
Phone: 407-377-6695
Email: info@nutriband.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: CorporateAds
Filed Under: Business
0 Comments
Latest on S For Story
- Letterhome Now Prints and Mails Letters and Postcards to the US, UK, Australia, Canada and More
- A Cache of Stolen Fate Magazines. Two Missing Parents. One Journalist Who Won't Stop Asking
- What If the Greatest Weapon of War Isn't a Bomb?
- Wordeee Announces Publication of "Hacking Heaven" by GJ Barbato
- Working the Front Desk by Night, Building a Brand by Day: Orlando Author Shantlee Campbell South
- Colorado Author Publishes Sequel in Middle-Grade Fantasy Series The Found Children
- Build Muscle at Home with The Samson II Program
- SpearPoint Ink Launches Two New Services to Help Business Experts Attract More Qualified Clients
- A Platypus, a Childhood Nickname, and a family secret walk into a Children's book
- New Textbook "Writing Speculative Fiction: A Guide" Bridges Theory and Narrative Design
- New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
- Jennifer Robin Barr Wins 2026 Grateful American Book Prize for "Thunder and Mercy"
- Technical Brief Examines Enterprise Integration Challenges as AI Agent Platforms Expand
- Children's Adventure Book "America's 250th Hags Champion" Turns Classic Playground Game Into a Myth
- The Well Woman Conference Comes To Philadelphia: A Powerful Experience Of Faith And Healing
- Provincetown Knitter Darren Showers Publishes Luna's Gift of Yarn
- Denry Okpor Publishes No One Is Coming, for Care Leavers Starting Again
- OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
- Kansas Trail Guide: The Best Hiking, Biking, and Riding in the Sunflower State, Second Edition
- New Book - Victory at Appomattox: Grant and Lee's Final Campaign by Hampton Newsome



